Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab/Tuvonralimab + Chemotherapy Followed by Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer
NCT07454018Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Mar 2026
- Primary completion
- Dec 2029
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab + tuvonralimab in ovarian cancer, sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Progression-Free Survival up to 24 months. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT07454018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07454018.